Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 10.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 561,231 shares of the company’s stock after selling 64,277 shares during the period. BNP Paribas Financial Markets’ holdings in Teva Pharmaceutical Industries were worth $17,516,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its holdings in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. Grove Bank & Trust lifted its holdings in Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Global Retirement Partners LLC lifted its holdings in Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. Finally, 1620 Investment Advisors Inc. lifted its holdings in Teva Pharmaceutical Industries by 1,823.2% in the 4th quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock valued at $49,000 after purchasing an additional 1,495 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total value of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares in the company, valued at approximately $6,131,472.24. This trade represents a 47.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at $2,825,792.40. The trade was a 64.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 421,470 shares of company stock worth $14,570,945. 0.54% of the stock is currently owned by insiders.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported new real-world survey data showing AUSTEDO and AUSTEDO XR improved quality-of-life measures for Huntington’s disease chorea patients and reduced caregiver strain, supporting the outlook for one of its key branded medicines. Article Title
• Positive Sentiment: Teva expanded its European biosimilars business with the launch of AHZANTIVE, strengthening its growth strategy and broadening its presence in ophthalmology. Article Title
• Neutral Sentiment: Industry coverage highlighted Teva as a generic-drug stock to watch as biosimilars, complex generics and specialty drugs become increasingly important growth drivers. Article Title

Teva Pharmaceutical Industries Trading Down 0.6%

Shares of TEVA stock opened at $34.21 on Friday. The firm has a market cap of $39.34 billion, a P/E ratio of 25.72, a PEG ratio of 3.49 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm’s 50-day simple moving average is $32.82 and its 200-day simple moving average is $31.63.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent research reports. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.